Table 4

Change in disease activity in each domain of the ESSDAI

DomainsTocilizumab W0
% of no/low/moderate/high		Tocilizumab W24
% of no/low/moderate/high		% improvement in tocilizumab groupPlacebo W0
% of no/low/moderate/high		Placebo W24
% of no/low/moderate/high		% improvement in placebo groupComparison of % improvement
% difference (95% CI)
Skinn=55
87.3/5.5/7.3/0		n=49
80.0/1.8/7.3/0		8.2n=54
87.3/5.5/1.8/3.6		n=50
85.5/1.8/3.6/0		8.0−0.2 (−11.7 to 11.3),
Pr(diff >0)=0.49
Pulmonaryn=55
80.0/14.5/3.6/1.8		n=49
80.0/5.5/3.6/0		12.2n=54
60.0/21.8/16.4/0		n=50
78.2/5.5/5.5/1.8		24.012.3 (−2.9 to 27.7),
Pr(diff >0)=0.94
Renaln=55
98.2/0/1.8/0		n=49
87.3/0/1.8/0		NAn=54
98.2/0/0/0		n=50
90.9/0/0/0		NA0 (−5.8 to 5.6),
Pr(diff >0)=0.5
Articularn=55
29.1/27.3/29.1/14.5		n=49
45.5/25.5/18.2/0		49.0n=54
23.6/34.5/23.6/16.4		n=50
49.1/16.4/20.0/5.5		46.0−2.9 (−21.8 to 16.3),
Pr(diff >0)=0.38
Muscularn=55
92.7/3.6/1.8/1.8		n=49
85.5/1.8/0/1.8		2.0n=54
94.5/1.8/1.8/0		n=50
89.1/1.8/0/0		2.0−0.1 (−7.8 to 7.6),
Pr(diff >0)=0.49
Peripheral neuropathyn=55
83.6/12.7/3.6/0		n=49
78.2/7.3/3.68/0		2.0n=54
81.8/3.6/12.7/0		n=50
81.8/3.6/5.5/0		12.09.5 (−0.6 to 20.8),
Pr(diff >0)=0.97
CNSn=55
98.2/0/1.8/0		n=49
87.3/0/1.8/0		NAn=54
98.2/0/0/0		n=50
90.9/0/0/0		NA0 (−5.8 to 5.6),
Pr(diff >0)=0.5
Glandularn=55
47.3/34.5/18.2		n=49
63.6/20.0/5.56		34.7n=54
47.3/29.1/21.8		n=50
63.6/16.4/10.9		34.0−0.7 (−18.9 to 17.5),
Pr(diff >0)=0.47
Constitutionaln=55
72.7/27.3/0		n=49
70.9/16.4/1.8		14.3n=54
70.9/25.5/1.8		n=50
80.0/10.9/0		20.05.5 (−9.3 to 20.3),
Pr(diff >0)=0.77
Haematologicaln=54
60.0/36.4/3.6/0		n=49
40.0/40/9.1/0		8.2n=54
54.5/38.2/5.5/0		n=50
49.1/38.2/1.8/1.8		18.09.4 (−3.8 to 23,0),
Pr(diff >0)=0.92
Lymphadenopathyn=54
85.5/10.9/1.8/0		n=49
87.3/1.8/0/0		14.6n=54
90.9/7.3/0/0		n=50
89.1/1.8/0/0		8.0−6.4 (−19.5 to 6.3),
Pr(diff >0)=0.16
Biologicaln=54
34.5/21.8/41.8		n=49
14.5/41.8/32.7		10.4n=54
45.5/21.8/30.9		n=50
43.6/20.0/27.3		8.0−2.4 (−14.6 to 9.6),
Pr(diff >0)=0.34

  • CNS, central nervous system; ESSDAI, European League Against Rheumatism Sjögren's Syndrome Disease Activity Index; NA, not assessed.